Sutro Biopharma to Participate in Upcoming Investor Conferences
August 30 2023 - 8:00AM
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a
clinical-stage oncology company pioneering site-specific and
novel-format antibody drug conjugates (ADCs), today announced that
Bill Newell, Chief Executive Officer, will participate in two
upcoming investor conferences.
Presentation Details:
Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate:
Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT
Location: Boston
2023 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate:
Thursday, September 7, 2023Time: 10:15 a.m. ET / 7:15 a.m. PT
Location: Boston
Webcasts of the fireside chats will be accessible through the
News & Events page of the Investor Relations section of the
company’s website at www.sutrobio.com. Archived replays will be
available for at least 30 days after the event.
About Sutro
Biopharma
Sutro Biopharma, Inc., headquartered in South San Francisco, is
a clinical-stage oncology company pioneering site-specific and
novel-format antibody drug conjugates (ADCs). Sutro has two wholly
owned ADCs in the clinic—luveltamab tazevibulin (STRO-002 or
luvelta), a folate receptor alpha (FolRα)-targeting ADC, in
clinical studies for ovarian and endometrial cancers; and STRO-001,
a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Additionally, Sutro is collaborating with Bristol Myers Squibb
(BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients
with multiple myeloma; with Merck, known as MSD outside of the
United States and Canada, on MK-1484, a selective IL-2 agonist in
clinical studies as a monotherapy and in combination with
pembrolizumab for the treatment of solid tumors; and with Astellas
Pharma (Astellas) on novel modality, immunostimulatory
antibody-drug conjugates (iADCs). Sutro’s platform technology also
enabled the spin out of Vaxcyte and the creation of VAX-24, a
24-valent pneumococcal conjugate vaccine in clinical studies for
the prevention of invasive pneumococcal disease. Sutro’s rational
design and precise protein engineering has enabled six product
candidates in the clinic. Follow Sutro on Twitter, @Sutrobio, and
at www.sutrobio.com to learn more about our passion for changing
the future of oncology.
ContactAnnie J. Chang Sutro Biopharma (650)
801-5728
ajchang@sutrobio.com
Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Apr 2024 to May 2024
Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From May 2023 to May 2024